upadacitinib Archives - Drugs in Context

JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review

Beatriz Henriques dos Santos, João Domingues, Marco Sousa, Tiago Torres

Article Type

Review

Published

22 Oct 2025

This narrative review evaluates current evidence on the efficacy and safety of JAK inhibitors in the treatment of palmoplantar pustulosis.

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature

Giuseppe Lopalco, Arianna D’Antonio, Maria Sole Chimenti, Florenzo Iannone

Article Type

Case Series & Review

Published

12 May 2025

Four case studies described here illustrate the effectiveness of upadacitinib in a range of real-world patients with axial spondyloarthritis.

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Novin Nezamololama, BSc, MSc, Keira Fieldhouse, BSc, Kristy Metzger, BSc, Melinda Gooderham, MD, MSc, FRCPC

Article Type

Review

Published

16 Nov 2020

This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of atopic dermatitis.

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Karel Pavelka MD PhD, Zoltán Szekanecz MD PhD DSc, Nemanja Damjanov MD PhD, Branimir Anić MD PhD, Matija Tomšič MD PhD, Vadim Mazurov MD PhD, Marija Maksimovic MD, Orsolya Nagy MD PhD, Jerzy Świerkot MD PhD, Tzvetanka Petranova MD PhD, Tiina Veldi MD, Asta Baranauskaitė MD PhD, Catalin Codreanu MD PhD, Daina Andersone MD PhD, Roy Fleischmann MD

Article Type

Original Research

Published

19 Oct 2020

This post hoc analysis of SELECT-COMPARE reports, for the first time, the efficacy and safety of upadacitinib 15 mg in combination with methotrexate
(MTX) in patients from the Central and Eastern European region with MTX inadequate response rheumatoid arthritis compared with placebo or adalimumab with MTX up to 48 weeks of follow-up.

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Martina Biggioggero MD, Andrea Becciolini MD, Chiara Crotti MD, Elena Agape MD, Ennio Giulio Favalli MD

Article Type

Review

Published

24 Oct 2019

This narrative review discusses the rationale for JAK inhibition in RA, with a special focus on the role of JAK1 selective blockade and a detailed description of available data from the results of clinical trials on upadacitinib and filgotinib.